Clinical Trial Update: Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating stereotactic body radiotherapy with or without pembrolizumab in adults with unresected stage I–II non-small cell lung cancer was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2025-05-11